The announcement of new preclinical data and strategic priorities is likely to be viewed positively by investors, as it demonstrates progress in Editas Medicine's research and development efforts. The focus on gene editing in non-human primates and humanized mice suggests potential advancements in their pipeline, which could lead to future clinical applications. This news is directly relevant to Editas Medicine and is important for investors as it outlines the company's future direction and potential for growth.